一区久久久av青青草原_国产三级在线观看一区_亚洲综合国产一区二区三区_国产一在线精品一区在线观看_亚洲国产韩国欧美在线

山東省人民政府網(wǎng)站顯示，根據(jù)《山東省科學(xué)技術(shù)獎(jiǎng)勵(lì)辦法》規(guī)定，經(jīng)省科學(xué)技術(shù)獎(jiǎng)勵(lì)評(píng)審委員會(huì)評(píng)審、省科學(xué)技術(shù)獎(jiǎng)勵(lì)委員會(huì)審定和省科技廳審核，2017年度山東省科學(xué)技術(shù)獎(jiǎng)勵(lì)出爐，山東省眼科研究所史偉云教授獲得山東省科學(xué)技術(shù)最高獎(jiǎng)，成為兩位最高獎(jiǎng)的獲得者之一。

作為全國(guó)人大代表，山東省眼科研究所所長(zhǎng)、黨委書記，中華醫(yī)學(xué)會(huì)眼科學(xué)分會(huì)常委、角膜病組組長(zhǎng)，山東省泰山學(xué)者攀登計(jì)劃專家，史偉云教授已從事眼科醫(yī)學(xué)三十多年。近年來，他先后榮獲中華眼科學(xué)會(huì)杰出成就獎(jiǎng)、吳階平—保羅·楊森醫(yī)學(xué)藥學(xué)獎(jiǎng)、美國(guó)眼科學(xué)會(huì)成就獎(jiǎng)等重量級(jí)獎(jiǎng)項(xiàng)，是當(dāng)下中國(guó)大陸眼科學(xué)領(lǐng)域最具代表性的專家之一。

據(jù)了解，史偉云教授首次提出的睫狀體－虹膜通路，是引起角膜移植排斥另一途徑的創(chuàng)新理論，并據(jù)此研發(fā)了我國(guó)首個(gè)具有獨(dú)立知識(shí)產(chǎn)權(quán)的眼內(nèi)植入緩釋藥物，獲得CFDA藥物臨床試驗(yàn)批件。

他還創(chuàng)新深板層角膜移植治療圓錐角膜的方法，打破了圓錐角膜只能行穿透性移植的傳統(tǒng)觀點(diǎn)。同時(shí)，與導(dǎo)師謝立信院士一起提出“不同真菌在角膜內(nèi)存在不同生長(zhǎng)方式”創(chuàng)新理論，打破了不能應(yīng)用板層角膜移植治療真菌性角膜炎的傳統(tǒng)觀點(diǎn)，使手術(shù)長(zhǎng)期成功率超過95％。創(chuàng)造性應(yīng)用多層羊膜移植治療基質(zhì)壞死型角膜炎，使這一世界難題取得突破性進(jìn)展。

目前，史偉云教授已累計(jì)為全國(guó)30余省市的1萬多名疑難角膜病患者實(shí)現(xiàn)復(fù)明，成為國(guó)內(nèi)極少獨(dú)立完成萬余例疑難角膜移植手術(shù)的眼科專家。

史偉云，現(xiàn)任山東省眼科研究所黨委書記、所長(zhǎng)，山東省眼科醫(yī)院院長(zhǎng)，是山東省泰山學(xué)者攀登計(jì)劃專家、山東省有突出貢獻(xiàn)的中青年專家、山東省首屆醫(yī)學(xué)領(lǐng)軍人才、第十三屆全國(guó)人民代表大會(huì)代表、中華醫(yī)學(xué)會(huì)眼科分會(huì)第十一屆委員會(huì)常務(wù)委員、角膜病學(xué)組組長(zhǎng)，中華眼科學(xué)分會(huì)專家委員，國(guó)務(wù)院特殊津貼享受者。

史偉云教授1989年開始跟隨我國(guó)著名眼科專家謝立信院士攻讀碩、博士，并獲眼科學(xué)博士學(xué)位。2000年赴美國(guó)，跟隨世界角膜病大師Kaufman教授繼續(xù)角膜病的基礎(chǔ)研究工作。2007年被青島大學(xué)、2008年被山東大學(xué)分別聘為博士生導(dǎo)師。

史偉云教授從事眼科基礎(chǔ)研究及臨床診治工作30余年，是山東大學(xué)、青島大學(xué)、濟(jì)南大學(xué)、濰坊醫(yī)學(xué)院眼科學(xué)教授和博士生導(dǎo)師，兼任《中華眼科雜志》副總編輯，《中華眼視光學(xué)與視覺科學(xué)雜志》、《中國(guó)眼耳鼻喉科雜志》、《臨床眼科雜志》、《眼科》編委、山東省眼科學(xué)分會(huì)副主任委員。

Congratulations! Prof. Weiyun SHI Won the Highest Science and Technology Award of Shandong Province

?

As reported on the official website of People’s Government of Shandong Province, according to the regulations in Reward Measures for Science and Technology Awards of Shandong Province, after the evaluation by the Evaluation Committee of the Provincial Science and Technology Awards, the approval by the Committee of the Provincial Science and Technology Awards and the review by the Department of Science and Technology of Shandong Province, the Shandong Provincial Science and Technology Awards of 2017 are published. Prof. Weiyun SHI of Shandong Eye Institute won the Highest Science and Technology Award of Shandong Province, becoming one of the two highest prize winners.

Prof. SHI, as a deputy to the National People’s Congress, the director and the secretary of the Party Committee of Shandong Eye Institute, a member of the Standing Committee of the Ophthalmology Society of Chinese Medical Association, the leader of the Corneal Group and an expert of Taishan Scholar Program of Shandong Province, has been engaged in ophthalmology for more than 30 years. In recent years, he has received many important awards such as the Outstanding Achievement Award of Chinese Ophthalmology Society, Wu Jieping Medical Research Award–Paul Janssen Pharmaceutical Research Award, the Achievement Award of American Academy of Ophthalmology. Professor SHI is one of the most representative experts in ophthalmology in mainland China.

The iris-ciliary body pathway, first proposed by Prof. SHI, is an innovative theory for corneal graft rejection. Based on this research achievement, he developed the first ocular implantable sustained-release drug with independent intellectual property in China and gained the clinical trial permission for drugs from CFDA.

Prof. SHI also made innovations in deep lamellar keratoplasty to treat keratoconus, breaking the traditional view that keratoconus can only be treated by penetrating keratoplasty. Prof. SHI also proposed an innovative theory that “different fungi have different growth patterns in the cornea” with Academician Lixin XIE, who is his supervisor, breaking the traditional view that lamellar keratoplasty cannot be used to treat fungal keratitis and achieving a long-term surgery success rate of more than 95%. The creative application of multilayer amniotic membrane transplantation by Prof. SHI is a breakthrough to the worldwide problem of treating necrotizing stromal keratitis.

Up to now, Prof. SHI has helped more than 10,000 patients with difficult corneal diseases from more than 30 provinces and cities nationwide to regain sight. Prof. SHI is one of the few ophthalmologists in China that have performed more than 10,000 difficult corneal transplantation surgeries independently.